Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06207734
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-01-03
Brief Title:
Discontinuation of CDK46 Inhibitors in Patients With Metastatic HR Positive HER2 Negative Breast Cancer
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Organization:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Study Overview
Official Title:
Discontinuation of CDK46 Inhibitors in Patients With Metastatic HR Positive HER2 Negative Breast Cancer With Durable Disease Control A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of Life
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a low-intervention randomized non-comparative open-label multicenter prospective phase II trial investigating discontinuation of CDK46 inhibitors in patients with metastatic HR positive HER2 negative breast cancer with durable disease control
Detailed Description:
The primary objective is to evaluate long-term disease stabilization of CDK46 inhibitors discontinuation after a prolonged treatment period with continued endocrine therapy in breast cancer patients exhibiting at least stable disease after at least 12 months of combination treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None